By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boston Therapeutics, Inc. 

1750 Elm Street
Suite 103
Manchester  New Hampshire  03104  U.S.A.
Phone: 603-935-9799 Fax: 603-685-4784



Company News
Boston Therapeutics' sugardown(R) In Clinical Trials Reduces Glucose, Fructose And Insulin 12/29/2015 9:00:47 AM
Boston Therapeutics Reports Third Quarter Results And Provides Corporate Update 11/23/2015 12:40:31 PM
Boston Therapeutics, Inc. Completes Enrollment For BTI-320 Clinical Trial 10/7/2015 1:20:38 PM
Boston Therapeutics, Inc. Pays Off Convertible Promissory Notes 10/1/2015 1:03:10 PM
Boston Therapeutics, Inc. Reports Second Quarter Results And Provides Corporate Update 8/14/2015 10:37:22 AM
Boston Therapeutics, Inc. Nominates Philip Getter To Board Of Directors 8/6/2015 10:03:56 AM
Boston Therapeutics, Inc. ' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point By Enrolling 30 Patients At The Chinese University Of Hong Kong 7/8/2015 10:46:59 AM
Boston Therapeutics, Inc. Presents Findings Of BTI-320, A Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate As Therapy To Manage Blood Glucose At 75th Annual Meeting Of The American Diabetes Association 6/9/2015 11:09:39 AM
Boston Therapeutics, Inc. & University at Buffalo's Translational Pharmacology Research Core Initiates BTI-320 Clinical Trials Alliance In Buffalo, NY And NYC's Chinatown 5/28/2015 10:52:54 AM
Boston Therapeutics, Inc. Reports First Quarter Results And Provides Corporate Update 5/21/2015 12:19:14 PM